{{Rsnum
|rsid=1883322
|Gene=PPARD
|Chromosome=6
|position=35402029
|Orientation=minus
|GMAF=0.3223
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PPARD
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 54.0 | 38.9 | 7.1
| HCB | 54.0 | 37.2 | 8.8
| JPT | 56.6 | 39.8 | 3.5
| YRI | 10.9 | 51.0 | 38.1
| ASW | 21.1 | 38.6 | 40.4
| CHB | 54.0 | 37.2 | 8.8
| CHD | 42.2 | 42.2 | 15.6
| GIH | 61.4 | 35.6 | 3.0
| LWK | 22.7 | 30.9 | 46.4
| MEX | 77.6 | 22.4 | 0.0
| MKK | 12.8 | 50.0 | 37.2
| TSI | 53.9 | 36.3 | 9.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1883322
|Name_s=PPARD:rs1883322 A>G
|Gene_s=PPARD
|Feature=
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: G Phenotype: The PPAR delta SNP rs1883322 A>G was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0061 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111525
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1883322
|overall_frequency_n=66
|overall_frequency_d=126
|overall_frequency=0.52381
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=53
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}